Moderate exacerbations (course of antibiotics or oral steroids) · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists probably leads to lower moderate exacerbations (course of antibiotics or oral steroids) compared with placebo (moderate certainty).
1 finding from 1 review
Moderate‐to‐severe exacerbations (rate) · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists showed no clear difference in severe/moderate exacerbations (hospitalisation or course of… compared with placebo (moderate certainty).
1 finding from 1 review
Mortality (all‐cause) · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists showed no clear difference in mortality (all‐cause) compared with placebo (moderate certainty).
1 finding from 1 review
Participants with one or more serious adverse event (non‐fatal) · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists showed no clear difference in participants with one or more serious adverse event (non‐fatal) compared with placebo (moderate certainty).
1 finding from 1 review
FEV1 · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists showed no clear difference in predose FEV1 (mL) compared with placebo (low certainty).
1 finding from 1 review
Health‐related quality of life (HRQL) · people with asthma
1 finding from 1 review
Adverse events · adults and children with exercise‐induced bronchoconstriction/asthma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Asthma exacerbations · people with asthma
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · people with asthma
1 finding from 1 review
Asthma symptoms · people with asthma
1 finding from 1 review
Adverse events · people with asthma
1 finding from 1 review
Health‐related quality of life (HRQL) · adults and children with exercise‐induced bronchoconstriction/asthma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Asthma exacerbations · adults and children with exercise‐induced bronchoconstriction/asthma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Lung function: FEV1 % drop Postexercise · adults and children with exercise‐induced bronchoconstriction/asthma
1 finding from 1 review
no estimate extracted
1 study · 8 participants
Low
Asthma symptoms · adults and children with exercise‐induced bronchoconstriction/asthma
1 finding from 1 review
no estimate extracted
1 study · 8 participants
Low
Hospital admissions · patients with acute asthma
ICS may leads to lower hospital admission compared with placebo (low certainty).
1 finding from 1 review
FEV1 (L) · patients with acute asthma
ICS showed no clear difference in FEV1 at 1 hour compared with placebo (low certainty).
1 finding from 1 review
FEV1 · patients with acute asthma
ICS showed no clear difference in FEV1 at 3 to 4 hours compared with placebo (moderate certainty).
1 finding from 1 review
Nausea and vomiting · patients with acute asthma
ICS showed no clear difference in adverse effects ‐ nausea/vomiting compared with placebo (low certainty).
1 finding from 1 review
PEF (L/min) · patients with adults with acute asthma
Aminophylline showed no clear difference in PEF (L/min) ‐ at 60 min compared with placebo (low certainty).
1 finding from 1 review